Literature DB >> 26997492

The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.

Emina Babarović1, Toni Valković2, Ivana Budisavljević2, Ivan Balen3, Sanja Štifter3, Antica Duletić-Načinović2, Ksenija Lučin3, Nives Jonjić3.   

Abstract

Several studies have shown a gradual increase in the extent of bone marrow angiogenesis in various stages of proliferative plasma cell disorders, from monoclonal gammopathy of undetermined significance (MGUS) to active multiple myeloma (MM). The main aim of this study was to evaluate tumor angiogenesis parameters in detail and to correlate them with the expression of osteopontin (OPN) and vascular endothelial growth factor (VEGF) in the bone marrow of patients with MGUS and MM. In addition, we wanted to determine their prognostic significance in active MM. Ninety-five patients were enrolled in the study: 14 diagnosed with MGUS, 13 with asymptomatic myeloma (AMM) and 68 with active MM. Computer assisted image analysis was used to determine the angiogenesis parameters, the quantity of microvessels per 1mm(2) (MVD), the area occupied by microvessels per 1mm(2) and the percentage of microvessel area in total section area (TVA). Double immunohistochemical methods CD138+VEGF and CD138+OPN were used to evaluate expression of these proteins in plasma cells, and OPN was also analyzed for its interstitial expression (iOPN). A significant positive correlation was determined between VEGF and iOPN with angiogenic parameters in the MGUS stage of the disease. In advanced stages of the disease, a significant negative correlation was recorded between OPN and iOPN with parameters of angiogenesis. Overall survival was significantly shorter for patients with negative iOPN (p=0.002) and higher angiogenic parameters, MVD (p=0.009), TVA (p=0.008) and area of microvessels per 1mm(2) (p=0.02). Positive VEGF expression in our model predicted a better three-year survival of patients with active MM (OR: 5.25, p=0.03; HR: 0.44, p=0.04). The results of our study suggested a possible key role of VEGF and OPN in the induction of angiogenesis in early-stage disease.
Copyright © 2016 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Osteopontin; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2016        PMID: 26997492     DOI: 10.1016/j.prp.2015.11.021

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  5 in total

Review 1.  Human osteopontin: Potential clinical applications in cancer (Review).

Authors:  Chengcheng Hao; Yuxin Cui; Sionen Owen; Wenbin Li; Shan Cheng; Wen G Jiang
Journal:  Int J Mol Med       Date:  2017-04-21       Impact factor: 4.101

2.  Adaptive Regulation of Osteopontin Production by Dendritic Cells Through the Bidirectional Interaction With Mesenchymal Stromal Cells.

Authors:  Sara Scutera; Valentina Salvi; Luisa Lorenzi; Giorgia Piersigilli; Silvia Lonardi; Daniela Alotto; Stefania Casarin; Carlotta Castagnoli; Erica Dander; Giovanna D'Amico; Silvano Sozzani; Tiziana Musso
Journal:  Front Immunol       Date:  2018-06-01       Impact factor: 7.561

3.  Estimation of Hub Genes and Infiltrating Immune Cells in Non-Smoking Females with Lung Adenocarcinoma by Integrated Bioinformatic Analysis.

Authors:  Jie Li; Ben Wang; Xin Li; Yuxi Zhu
Journal:  Med Sci Monit       Date:  2020-07-16

Review 4.  The Role of Extracellular Matrix Proteins in Breast Cancer.

Authors:  Arkadiusz Lepucki; Kinga Orlińska; Aleksandra Mielczarek-Palacz; Jacek Kabut; Pawel Olczyk; Katarzyna Komosińska-Vassev
Journal:  J Clin Med       Date:  2022-02-25       Impact factor: 4.241

5.  High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma.

Authors:  Normann Steiner; Roman Hajek; Sabina Sevcikova; Bojana Borjan; Karin Jöhrer; Georg Göbel; Gerold Untergasser; Eberhard Gunsilius
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.